Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026 BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

PRNewsWire • Feb 19, 2026

Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products

Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costs BOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo") and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs. Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chemistry.

PRNewsWire • Feb 18, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts

The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $9, representing a -3.12% change from its previous close.

Zacks Investment Research • Feb 18, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know

Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.23 at the closing of the latest trading day, reflecting a -9.06% change compared to its last close.

Zacks Investment Research • Feb 11, 2026

Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark

Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratory Preprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesis GPT-5-driven autonomous lab executed over 36,000 experiments Ginkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven science BOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free protein synthesis reaction costs by 40% relative to state of the art, while running 36,000 experimental conditions across six iterative cycles.

PRNewsWire • Feb 5, 2026

Why Ginkgo Bioworks Holdings, Inc. (DNA) Dipped More Than Broader Market Today

In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $8.27, denoting a -5.92% move from the preceding trading day.

Zacks Investment Research • Feb 5, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Declines More Than Market: Some Information for Investors

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $9.31, signifying a -1.27% move from its prior day's close.

Zacks Investment Research • Jan 30, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Drops Despite Market Gains: Important Facts to Note

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $10.02, marking a -6.36% move from the previous day.

Zacks Investment Research • Jan 24, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Increases Despite Market Slip: Here's What You Need to Know

In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.85, indicating a +2.39% shift from the previous trading day.

Zacks Investment Research • Jan 15, 2026

Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m.

PRNewsWire • Jan 13, 2026